Bio-Techne Corp (TECH) has seen fluctuating market activity, with stocks being adjusted by several investment companies. Prominent entities such as
Neuberger Berman Group LLC and
Cramer Rosenthal Mcglynn LLC have boosted their respective holdings in TECH, while others like
JPmorgan Chase & Co. and
Citigroup Inc. have trimmed their stakes. The company's
first quarter of
fiscal 2026 results were reported, although lacking luster, sparking some optimism owing to strategic navigation through challenges. Recently, another round of growth was seen, following the attainment of
Ella's CE-IVD milestone and increased prospects in Diagnostics. However, not all forecasts have been positive. Analysts have mentioned that, despite the recent rebound in stock price, it may still be fair to question the pricing. Nonetheless, the company continues to innovate, recently partnering with the
Wyss Center Geneva to advance automated 3D multiomics technology and spatial biology. Moreover, the company's Ella platform has achieved
CE-IVD marking, which should expand access to rapid, cartridge-based immunoassays for European clinical laboratories.
Bio-Techne Corp TECH News Analytics from Wed, 25 Jun 2025 07:00:00 GMT to Sat, 07 Mar 2026 11:58:20 GMT -
